Bone Positron Emission Tomography with or without CT Is More Accurate than Bone Scan for Detection of Bone Metastasis

Soo Jin Lee, MD, PhD, Won Woo Lee, MD, PhD, Sang Eun Kim, MD, PhD

1Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 463-707, Korea; 2Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-744, Korea

Objective: Na\textsuperscript{18}F bone positron emission tomography (bone PET) is a new imaging modality which is useful for the evaluation of bone diseases. Here, we compared the diagnostic accuracies between bone PET and bone scan for the detection of bone metastasis (BM).

Materials and Methods: Sixteen cancer patients (M:F = 10:6, mean age = 60 ± 12 years) who underwent both bone PET and bone scan were analyzed. Bone PET was conducted 30 minutes after the injection of 370 MBq Na\textsuperscript{18}F, and a bone scan was performed 3 hours after the injection of 1295 MBq 99mTc-hydroxymethylene diphosphonate.

Results: In the patient-based analysis (8 patients with BM and 8 without BM), the sensitivities of bone PET (100% = 8/8) and bone scan (87.5% = 7/8) were not significantly different (p > 0.05), whereas the specificity of bone PET (87.5% = 7/8) was significantly greater than that of the bone scan (25% = 2/8) (p < 0.05). In the lesion-based analysis (43 lesions in 14 patients; 31 malignant and 12 benign), the sensitivity of bone PET (100% = 31/31) was significantly greater than that of bone scan (38.7% = 12/31) (p < 0.01), and the specificity of bone PET (75.0% = 9/12) was also significantly higher than that of bone scan (8.3% = 1/12) (p < 0.05). The receiver operating characteristic curve analysis showed that bone PET was significantly more accurate than the bone scan in the patient (p = 0.0306) and lesion (p = 0.0001) based analyses.

Conclusion: Na\textsuperscript{18}F bone PET is more accurate than bone scan for BM evaluation.

Index terms: Na\textsuperscript{18}F; Positron emission tomography; Positron emission tomography/computed tomography; 99mTc-HDP; Bone scan; Bone metastasis

INTRODUCTION

Na\textsuperscript{18}F is a very useful imaging agent for the evaluation of bone abnormality. Owing to its high bone affinity, rapid clearance, and low protein binding, Na\textsuperscript{18}F is superior to 99mTc-labeled phosphate agents in terms of bone image quality (1, 2). Furthermore, the fast kinetics of Na\textsuperscript{18}F enables image acquisition as early as 30 minutes post injection, improving patient compliance (3, 4). In fact, Na\textsuperscript{18}F has been introduced as a bone imaging agent for positron emission tomography (PET) since the 1960s (5). However, bone PET using Na\textsuperscript{18}F could not be routinely used in clinical practice during those years due to the undeveloped PET imaging technology. The advent of gamma imaging technology and the development of 99mTc-labeled phosphate agents in the 1970s have almost replaced bone imaging.
PET with the bone scan (6).

The recent innovative advancement of the PET technique allowed Na\(^{18}\)F to resurface as a promising bone imaging agent (3, 7). The resolution of PET was superior to that of gamma camera imaging. PET integrated with CT, yielding PET/CT, further improved the lesion detection rate with the aid of anatomical information from the CT. Thanks to the effective attenuation correction algorithm, PET generated a more accurate quantitative image data set than gamma camera imaging (7-9). Furthermore, the supply crisis of \(^{99}\)Mo, the parent radionuclide of \(^{99m}\)Tc, in 2010 had many physicians pay more attention to the usefulness of bone PET using Na\(^{18}\)F (1, 4). Bone PET has been proven to be useful for a variety of bone diseases. Bone PET is able to effectively evaluate not only malignant diseases (8-10), but also benign bone diseases (11-13). Previously, we reported the utility of bone PET for the evaluation of bone abnormalities for the first time in Korea (14). However, in the previous study, bone PET was not directly compared to the bone scan for the detection rate of bone metastasis (BM). Thus, in the current study, we aimed to compare the diagnostic accuracies between bone PET and bone scan in cancer patients who underwent both imaging studies.

**MATERIALS AND METHODS**

**Subjects**

Sixteen cancer patients (M:F = 10:6, mean age = 60 ± 12) were enrolled in this study. Eleven of these patients were included in our previous report (14), which did not involve the head-to-head comparison between the bone scan and the bone PET. Underlying diseases of the patients included breast cancer (n = 5), prostate cancer (n = 5), thyroid cancer (n = 3), gastric cancer (n = 1), colon cancer (n = 1), and larynx cancer (n = 1) (Table 1). The bone scan and the bone PET were performed within 1 month apart from each other. The reasons for the bone evaluation were regular follow-up (n = 10), presence of suspicious BM (n = 5), and post-therapeutic evaluation of the known BM (n = 1). This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital.

**Bone Scan**

A bone scan was performed using \(^{99m}\)Tc-hydroxymethylenediphosphonic acid (HDP, Mallinckrodt, St. Louis, MO, USA). The dose of \(^{99m}\)Tc-HDP was 1295 MBq (= 35 mCi). Whole body bone scan images were acquired using a dual-head gamma camera (Forte, ADAC-Philips, Holt, MO, USA) equipped with low energy high resolution collimator 3 hours post \(^{99m}\)Tc-HDP injection.

**Na\(^{18}\)F Bone PET**

For the bone PET image acquisition, no particular patient preparation was required. Na\(^{18}\)F was generated from a reaction of \(^{18}\)O (p, n)\(^{18}\)F using an in-house cyclotron (Kotron13, KIRAMS, Seoul, Korea). 370 MBq (= 10 mCi) of Na\(^{18}\)F was injected into the patients. Ten minutes later, furosemide (10 mg, Lasix) was injected in order to flush the activity of the renal pelvis or urinary excretory system. Bone PET images were obtained from the skull base to the upper thigh or from the skull vertex to the feet, as requested by the physicians who had set the orders starting 30 minutes post Na\(^{18}\)F injection. A dedicated PET scanner (Allegro, Philips Medical Systems, Andover, MA, USA) was used for 9 patients prior to the year 2009 (14) and a PET/CT scanner (DVCT, GE Healthcare, Milwaukee, WI, USA) was used for 7 patients afterwards. PET images from the dedicated PET scanner were attenuation-corrected using \(^{137}\)Cs transmission scans and then reconstructed using an iterative algorithm (Row-Action Maximum-Likelihood, Philips Medical Systems, Andover, MA, USA). PET/CT images were attenuation-corrected using the CT scan and then reconstructed using a 3-dimensional ordered-subset iteration algorithm (VUE point, GE Healthcare, Milwaukee, WI, USA). The resolutions of the reconstructed trans-axial images were 4.8 mm and 5.1 mm for PET and PET/CT, respectively.

**Interpretation of Bone PET and Bone Scan**

A positive finding for BM was defined as the presence of an abnormally high bony uptake, which is not associated with typical degenerative, traumatic or periarticular lesions (8). Diagnostic accuracies were also analyzed using the receiver operating characteristic (ROC) curve analysis by utilizing a 4-point grading system; definite, probable, less likely, and no evidence of BM. Consensus was reached by two nuclear medicine physicians in order to call a lesion BM.

A gold standard for BM was either the presence of typical findings compatible with BM in at least 2 imaging studies among MRI, \(^{18}\)F-FDG PET/CT or \(^{131}\)I whole body scan, or the presence of a clinical progression causing a change of treatment plan during at least a one-year follow-up. Those who had at least one proven BM lesion were considered BM positive patients regardless of the presence of any false
| No. | Age | Sex | Underlying Cancer | 99mTc-HDP Bone Scan | Na18F Bone PET | Final Results of Individual Lesions | PET or PET/CT |
|-----|-----|-----|-------------------|---------------------|----------------|-----------------------------------|---------------|
|     |     |     |                   | No. of Lesions Observed | Diagnostic Accuracy | No. of Lesions Observed | Diagnostic Accuracy |                           |               |
|     |     |     |                   | Patient | Lesion | Patient | Lesion |                           |               |
| 1   | 55  | M   | Gastric Ca.       | Numerous | TP     | Numerous | TP     | Innumerable BM             | PET           |
| 2   | 84  | M   | Prostate Ca.      | Numerous | TP     | Numerous | TP     | Innumerable BM             | PET           |
| 3   | 44  | F   | Breast Ca.        | 3       | TP     | 3 TP (15 FN) | 18    | 18 BM                      | PET/CT         |
| 4   | 65  | M   | Prostate Ca.      | 5       | TP     | 5 TP (1 FN) | 6     | 6 BM                       | PET/CT         |
| 5   | 49  | F   | Breast Ca.        | 2       | TP     | 2 TP (1 TN, 2 FN) | 5     | 4 TP, 1 FP   | 4 BM, 1 benign | PET           |
| 6   | 61  | M   | Prostate Ca.      | 2       | TP     | 1 TP, 1 FP | 2     | 1 TP, 1 FP   | 1 BM, 1 benign | PET           |
| 7   | 47  | F   | Breast Ca.        | 1       | TP     | 1 TP     | 1     | 1 BM                     | PET           |
| 8   | 65  | M   | Prostate Ca.      | 1       | FN     | 1 FN     | 1     | 1 TP                     | PET/CT         |
| 9   | 39  | M   | Thyroid Ca.       | 1       | FP     | 1 FN     | 1     | 1 FN                     | PET/CT         |
| 10  | 47  | F   | Thyroid Ca.       | 4       | FP     | 4 FP     | 0     | 4 TN                     | PET           |
| 11  | 63  | F   | Breast Ca.        | 1       | FP     | 1 FP     | 0     | 1 TN                     | PET           |
| 12  | 63  | M   | Thyroid Ca.       | 2       | FP     | 2 FP     | 0     | 2 TN                     | PET           |
| 13  | 45  | F   | Breast Ca.        | 1       | FP     | 1 FP     | 0     | 1 TN                     | PET           |
| 14  | 77  | M   | Colon Ca.         | 1       | FP     | 1 FN     | 0     | 1 TN                     | PET/CT         |
| 15  | 68  | M   | Laryngeal Ca.     | 0       | TN     | 0 TN     | 0     | 0                       | PET/CT         |
| 16  | 69  | M   | Prostate Ca.      | 0       | TN     | 0 TN     | 0     | 0                       | PET/CT         |

**Note.**—Gold standard for BM was either presence of typical findings compatible with BM in at least 2 imaging studies among MRI, 18F-FDG PET/CT, or 131I whole body scan, or presence of clinical progression causing change of treatment plan during at least one-year follow-up. BM = bone metastasis, TP = true positive, TN = true negative, FP = false positive, FN = false negative, PET = positron emission tomography.
positive BM findings.

**Statistical Analysis**

The comparison was performed on the basis of individual patient or bone lesion. McNemar’s chi-square test or Fisher’s exact test or ROC analysis was used for the comparison of the diagnostic accuracy. A *p*-value of less than 0.05 was considered significant.

**RESULTS**

**Patient-Based Analysis**

Of the 16 patients in the current study, 8 (50.0%) proved to be BM positive and 8 (50.0%) as BM negative. Of the 8 BM (+) patients, 2 had disseminated metastatic lesions, as shown in Figure 1. All of the 8 BM (+) patients were categorized as having BM in the bone PET, yielding 100% sensitivity, whereas 7 of the 8 BM (+) patients were positive in the bone scan, yielding an 87.5% sensitivity; the sensitivities were not statistically different between the bone PET and the bone scan (*p* > 0.05).

Of the 8 BM (-) patients, 7 were correctly categorized as having no BM in the bone PET, yielding an 87.5% (7/8) specificity, whereas only 2 were correctly diagnosed in the bone scan, yielding a 25.0% (2/8) specificity. As a result, a bone PET had a significantly higher specificity than a bone scan in the patient-based analysis (*p* < 0.05). A case showing higher specificity of a bone PET than a bone scan is demonstrated in Figure 2.

Overall, the accuracy of bone PET (93.8% = 15/16) was significantly greater than that of the bone scan (56.3% = 9/16, *p* < 0.05) in the patient-based analysis (Table 2).

**Lesion-Based Analysis**

Lesion-based analysis was conducted for the bone lesions identified by imaging studies, namely bone PET, bone scan, or CT. This is because benign bone lesions without abnormal findings in the imaging studies cannot be the lesions of interest in clinical practice. In addition, 2 patients who had innumerable BM lesions (Fig. 1, Table 1) were excluded in the lesion-based analysis because it was not sensible to identify a few more lesions in the clinical context of disseminated BM. As a result, 43 bone lesions were found in 14 patients. Of the 43 lesions, 31 were proven to be malignant and 12 were benign.

All of the 31 BM lesions were positive in the bone PET (sensitivity 100% = 31/31), whereas only 12 BM lesions were positive in the bone scan (sensitivity 38.7% = 12/31). As a result, bone PET was found to be significantly more sensitive than the bone scan (*p* < 0.01) (Fig. 3). Specificity was also significantly greater for bone PET (75% = 9/12) than the bone scan (8.3% = 1/12) (*p* < 0.05). Overall, the accuracy of bone PET (93.0% = 40/43) was significantly greater than that of the bone scan (30.2% = 13/43, *p* <
False Positive Findings of Bone PET

Three false positive bone PET lesions were noted in 3 patients (nos. 5, 6, and 9). The first two were sacrum and rib lesions from patients with spinal bone metastases proven by a spine MRI. With regard to the other proven bone metastases, the two lesions were strongly suggested to be clinical metastatic lesions. However, bone PET positive sacral lesion was negative in 18F-FDG PET/CT, while other bone PET positive lesions were all positive in the same patient. In addition, bone PET positive rib lesion was clinically stable without any evidence of a disease progression for 4 years and 2 months afterward. Thus, the 2 lesions were considered to be benign. For the last bone lesion in patient no.9 (Fig. 4), the rib lesion appeared to be positive in both the bone scan and the bone PET; however, it was negative on the 18F-FDG PET/CT and the 131I whole body scan. Serum thyroglobulin (< 0.2 ng/mL) and anti-thyroglobulin antibody (< 25 U/mL) were undetectable. The lesion was considered to be a benign lesion because other imaging studies were all negative; moreover, there was no evidence of a disease progression thereafter for more than one year.

ROC Curve Analysis

In the ROC curve analyses, the bone PET was significantly more accurate than the bone scan for the detection of BM. In the patient-based analysis, the area under the curve

| Table 2. Diagnostic Accuracy of Bone PET vs. Bone Scan in Patient-Based Analysis (n = 16) |
|-----------------------------------------------|
| Bone PET | Bone Scan | P    |
| Sensitivity | 100% (8/8) | 87.5% (7/8) | Not significant |
| Specificity | 87.5% (7/8) | 25.0% (2/8) | < 0.05 |
| Accuracy | 93.8% (15/16) | 56.3% (9/16) | < 0.05 |

Note.— PET = positron emission tomography

0.005) in the lesion-based analysis (Table 3).
Bone PET has been proven to be a useful bone imaging modality worldwide (1, 4). The combination of excellent physico-chemical characteristics of Na$^{18}$F and robust imaging techniques of modern PET scanner enabled the bone PET to be the most promising tool for bone imaging. Not only malignant bone diseases (8-10), but benign metabolic bone diseases (11-13) have also been successfully investigated using the bone PET. Furthermore, PET integrated with CT, yielding PET/CT, increased the diagnostic accuracy of bone PET in a variety of bone diseases (16).

In Korea, there has been only one clinical report on Na$^{18}$F bone PET (14). The study investigated only the feasibility of Na$^{18}$F bone PET in both cancer and benign bone disease patients. However, a critical question regarding the diagnostic accuracy of bone PET vs. bone scan for the detection of BM has not been addressed in the previous report. Thus, in the current study, we performed a direct comparison between the diagnostic accuracies of Na$^{18}$F bone PET vs. $^{99m}$Tc-HDP bone scan in cancer patients who underwent both imaging studies. The major finding of the current study is that the bone PET was found to be more accurate than the bone scan in the evaluation of BM and further, bone PET was shown to improve the sensitivity (in the lesion-based analysis) and specificity for BM.

Bone PET could effectively exclude non-metastatic bone lesions, which was reflected by its high specificity.

Bone PET with or without CT versus Bone Scan for Bone Metastasis Detection

Table 3. Diagnostic Accuracy of Bone PET vs. Bone Scan in Lesion-Based Analysis (n = 43)

|                | Bone PET | Bone Scan | P    |
|----------------|----------|-----------|------|
| Sensitivity    | 100% (31/31) | 38.7% (12/31) | < 0.01 |
| Specificity    | 75% (9/12) | 8.3% (1/12) | < 0.05 |
| Accuracy       | 93.0% (40/43) | 30.2% (13/43) | < 0.005 |

Note.— PET = positron emission tomography

AUC) of the bone PET (AUC = 0.992, standard error [SE] = 0.0110, 95% confidence interval [CI] = 0.781-1.000) was significantly higher than that of the bone scan (AUC = 0.750, SE = 0.118, 95% CI = 0.476-0.927) ($p = 0.0306$). In addition, in the lesion-based analysis, the AUC of the bone PET (AUC = 0.976, SE = 0.0155, 95% CI = 0.876-0.999) was significantly greater than that of the bone scan (AUC = 0.691, SE = 0.0752, 95% CI = 0.532-0.823) ($p = 0.0001$) (Fig. 5).

Bone PET vs. Bone PET/CT

The diagnostic accuracies were compared between bone PET and bone PET/CT. No difference was observed between the two studies in both patient and lesion-based analyses (Table 4).

DISCUSSION

Bone PET has been proven to be a useful bone imaging modality worldwide (1, 4). The combination of excellent physico-chemical characteristics of Na$^{18}$F and robust imaging techniques of modern PET scanner enabled the bone PET to be the most promising tool for bone imaging. Not only malignant bone diseases (8-10), but benign metabolic bone diseases (11-13) have also been successfully investigated using the bone PET. Furthermore, PET integrated with CT, yielding PET/CT, increased the diagnostic accuracy of bone PET in a variety of bone diseases (16).

In Korea, there has been only one clinical report on Na$^{18}$F bone PET (14). The study investigated only the feasibility of Na$^{18}$F bone PET in both cancer and benign bone disease patients. However, a critical question regarding the diagnostic accuracy of bone PET vs. bone scan for the detection of BM has not been addressed in the previous report. Thus, in the current study, we performed a direct comparison between the diagnostic accuracies of Na$^{18}$F bone PET vs. $^{99m}$Tc-HDP bone scan in cancer patients who underwent both imaging studies. The major finding of the current study is that the bone PET was found to be more accurate than the bone scan in the evaluation of BM and further, bone PET was shown to improve the sensitivity (in the lesion-based analysis) and specificity for BM.

Bone PET could effectively exclude non-metastatic bone lesions, which was reflected by its high specificity.
compared to the bone scan in both patient- and lesion-based analyses. The improved specificity of the bone PET compared to the bone scan seems to be mostly due to the tomographic nature of a PET and/or supplemental information from a CT (1, 4, 15). Planar bone scan images often fail to give confidence to readers regarding the exact location of the bone lesions due to the lack of depth information. On the contrary, bone PET is an inherently tomographic imaging modality with or without CT. Of course, if we had adopted a single photon emission computed tomography (SPECT) instead of the simple planar bone scan, the diagnostic accuracy of $^{99m}$Tc-HDP bone imaging would have been better (16), although a whole body coverage by SPECT might have been unrealistic due to the limited axial field of view of the current gamma camera. Another reason for the high specificity of bone PET compared to a bone scan also could be explained by the way the patients were recruited to the current study. Bone scan has already been proven to be useful as an initial screening test for BM evaluation (6, 15), and patients without any abnormality on their bone scans are not regarded as candidates for further tests, such as bone PET. Therefore, due to the test referral bias, true negative bone scan cases are typically excluded in this kind of retrospective study, resulting in a low specificity of the bone scan.

Bone PET sensitivity for individual metastatic lesions was superior to the bone scan. However, bone PET and bone scan had comparable sensitivities in the patient-based analysis (Table 2). With regard to the sensitivity of BM, bone PET seems to have a physico-chemical advantage over the bone scan (8, 17). The high first-pass extraction, rapid blood clearance, and low protein binding of $^{18}$F provide bone PET imaging with a high image-quality and a high lesion-contrast (3, 7). In our cases, bone PET

---

**Fig. 4. Case demonstration showing false positivity of bone positron emission tomography (PET) and bone scan in 39-year-old male patient with thyroid cancer (no.9 in Table 1).**

A. (left, bone scan posterior planar; middle, bone PET posterior maximum-intensity projection [MIP]; and right, $^{18}$F-FDG PET posterior image) Bone scan and bone PET revealed abnormal uptake in left 7th rib posterior arc (black arrows); however, $^{18}$F-FDG PET was negative in left 7th rib area. B. (left, CT; middle, fusion of bone PET/CT; and right, fusion of $^{18}$F-FDG PET/CT) CT revealed osteosclerotic lesion in left 7th rib posterior arc, which was compatible with hot uptake in bone PET/CT; however, lesion was negative in $^{18}$F-FDG PET/CT (white arrows). C. Posterior image of $^{131}$I whole body scan obtained 2 days after administration of $^{131}$I (30 mCi). No lesion was found in left 7th rib area.
Bone PET with or without CT versus Bone Scan for Bone Metastasis Detection

Table 4. Diagnostic Accuracy of Bone PET vs. Bone PET/CT in Patient and Lesion-Based Analyses

|                      | Patient-Based Analysis (n = 16) | Lesion-Based Analysis (n = 43) |
|----------------------|---------------------------------|--------------------------------|
|                      | Bone PET (n = 9) | Bone PET/CT (n = 7) | P     | Bone PET (n = 16) | Bone PET/CT (n = 27) | P     |
| Sensitivity          | 100% (5/5)       | 100% (3/3)          | NS    | 100% (6/6)       | 100% (25/25)         | NS    |
| Specificity          | 100% (4/4)       | 75% (3/4)           | NS    | 80% (8/10)       | 50% (1/2)            | NS    |
| Accuracy             | 100% (9/9)       | 85.7% (6/7)         | NS    | 87.5% (14/16)    | 96.3% (26/27)        | NS    |

Note.— NS = not significant, PET = positron emission tomography

clearly showed a more prominent uptake pattern compared to the bone scan in most of the BM lesions (Figs. 1-3), providing the readers with more confidence in the reading. Nevertheless, given the comparable sensitivity in the patient level (Table 2) and the relatively low cost, the bone scan may continue to be the primary screening study for the evaluation of BM for the time being. In fact, one crucial obstacle in the clinical application of bone PET is the cost-effectiveness of bone PET over the bone scan (10).

In addition, there are several advantages of bone PET over the bone scan. First, PET imaging is quantitative, whereas gamma camera imaging is not (1, 4, 7). Bone blood flow and bone turnover could be quantitatively measured using dynamic Na18F PET studies in malignant bone disease, Paget disease, or renal osteodystrophy (3, 11, 18, 19). Second, patient compliance for a bone PET should be better than that for a bone scan because it only takes about 0.5-1 hour for a bone PET acquisition in order to get started after the injection, which is shorter than the time for a bone scan, which takes at least 3-4 hours. Third, none-medical issues, such as the supply problem of 99Mo and the parent radionuclide of 99mTc may advance the clinical use of Na18F bone PET faster than expected. In this regard, physicians need to increase their awareness and pay closer attention to the development of Na18F bone PET in the future.

In conjunction with all the mentioned points above, the unique strength of the current study could be the comparison of the diagnostic accuracies between bone PET/CT and bone PET. Although the analyzed number of patients (n = 16) or lesions (n = 43) were quite low compared to other studies, the competency of bone PET was not inferior to that of bone PET/CT (Table 4). Although bone PET/CT may be more accurate for the identification of a particular BM lesion than the bone PET (Fig. 2), overall, the two studies were equivalent in terms of detection of BM in the level of patients and individual lesions (Table 4). If the results could be advocated in other larger scale studies, it might provide some chances of clinical utility to the outdated dedicated PET scanners in a few hospitals in Korea, including one in our hospital.

Limitation

The small sample size in the present study may have biased the final results. The characteristics of BM (i.e., osteoblastic, osteolytic, or mixed) or the known predilection site of BM may also have played some roles for determining the diagnostic accuracy of the bone PET. The heterogeneity of patient diseases also may have affected
the low diagnostic accuracy of the bone scan; particularly with single malignant disease patients, such as breast cancer, a bone scan may have a better diagnostic accuracy than other studies (20, 21). Furthermore, the fact that not all of the suspicious lesions were pathologically proven is another critical limitation of the study. 100% sensitivity of bone PET in the current study may overestimate the genuine diagnostic accuracy of the bone PET. Some bone metastatic lesions have been reported to be contained within the bone marrow without involving the cortical bone (22). If we had performed more 18F-FDG PET/CT studies, such BM lesions may have been missed by the bone PET, but observed by 18F-FDG PET/CT, generating a sensitivity of bone PET to be lower than 100%. 18F-FDG PET has been reported to be more accurate than 99mTc-MDP bone scan (21); however, 18F-FDG PET seems to have a lower accuracy for BM than Na18F bone PET (14). As a matter of fact, not only 18F-FDG PET/CT, but also MRI sometimes offers equivocal findings regarding the nature of bone lesions (20). Without a doubt, a bone biopsy would determine the exact nature of the bone lesion; yet, it is not always a practical approach for patient management. Furthermore, the cost-effectiveness of a bone PET was not evaluated in this study. In this regard, further large scale studies are required to determine the role of the bone PET for the evaluation of BM in the current medical reimbursement condition of Korea.

Conclusion

Na18F bone PET is more accurate than 99mTc-HDP bone scan for the evaluation of BM. Bone PET by itself has a potential to be a gold standard test for BM. However, without sufficient confirmatory data in Korea, we claim, solely from our findings, that the accuracy of bone PET is superior to that of the bone scan.

REFERENCES

1. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49:68-78
2. Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012;14:252-259
3. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr 1993;17:34-41
4. Czernin J, Satyamurthi N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med 2010;51:1826-1829
5. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962;3:332-334
6. Thrall JH. Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev Clin Radion Nucl Med 1976;8:1-31
7. Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992;33:633-642
8. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glattling G, Rentschler M, et al. Sensitivity in detecting osseus lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623-1629
9. Schirrmeister H, Glattling G, Hetzel J, Nüssle K, Arslan Demir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800-1804
10. Hetzel M, Arslan Demir C, König HH, Buck AK, Nüssle K, Glattling G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003;18:2206-2214
11. Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab 1997;77:949-955
12. Installé J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M. (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone. J Nucl Med 2005;46:1650-1658
13. Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. J Nucl Med 2009;50:1808-1814
14. Kang JY, Lee WW, So Y, Lee BC, Kim SE. Clinical Usefulness of 18F-fluoride Bone PET. Nucl Med Mol Imaging 2010;44:55-61
15. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-1367
16. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-297
17. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-2389
18. Schiepers C, Nuys J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 1997;38:1970-1976
19. Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I.
Quantification of skeletal kinetic indices in Paget’s disease using dynamic 18F-fluoride positron emission tomography. *J Bone Miner Res* 2002;17:854-859

20. Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. *AJR Am J Roentgenol* 2005;184:1266-1273

21. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. *J Nucl Med* 2007;48:889-895

22. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. *Semin Nucl Med* 2006;36:73-92